Lonza

Lonza is a leading CDMO for bioconjugates, supporting over 100 ADC programs since 2006. Our integrated offering spans from late-stage discovery to commercial manufacturing, leveraging deep expertise across the four key ADC modalities: mammalian, payload-linkers, bioconjugation, and fill-finish.

Beyond GlycoConnect® bioconjugation technology, Lonza offers a diverse portfolio of conjugation technologies and continually expands its capabilities through the development and acquisition of innovative solutions for next-generation bioconjugates.

Together, these technologies enable the development of best-in-class antibody-drug conjugates and other targeted therapies, supporting enhanced efficacy, improved tolerability, and accelerated development timelines for partners advancing innovative medicines.

With continued investment in large scale manufacturing, advanced conjugation technologies, and drug product filling, Lonza partners with biotechs and pharma companies to bring innovative therapies to patients efficiently, safely, and at scale.

Contact us and/or visit our website to find out more.